<DOC>
	<DOCNO>NCT00773526</DOCNO>
	<brief_summary>This study determine maximum tolerate dose dose limit toxicity ( Part 1 study ) activity ( Part 2 study ) RO5126766 patient metastatic advance solid tumor . In first part study , group patient sequentially enrol receive ascend oral dos RO5126766 daily 28 day . The start dose 0.1mg escalated subsequent group patient successful assessment safety tolerability previous dose . In Part 2 study , patient select tumor type randomize receive either optimal biological dose maximum tolerate dose RO5126766 daily . The anticipated time study treatment disease progression , target sample size 100 individual .</brief_summary>
	<brief_title>A Dose-Escalation Study RO5126766 Patients With Advanced Solid Tumors .</brief_title>
	<detailed_description />
	<criteria>adult patient , &gt; =18 year age ; advanced and/or metastatic cancer amenable standard therapy ; solid tumor type ( Part 1 ) ; malignant melanoma , pancreatic cancer nonsmall cell lung cancer ( Part 2 ) ; measurable and/or evaluable disease ( Part 1 ) , &gt; =1 measurable lesion ( Part 2 ) ; ECOG performance status 01. prior chemotherapy , radiotherapy immunotherapy within 28 day first receipt study drug ; prior corticosteroid anticancer therapy within 14 day first receipt study drug ; know past present CNS metastasis ; acute chronic infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>